ArticleJournal of food and drug analysis2026
Simotang oral liquid alleviates functional dyspepsia-related motility dysfunction through Ca
Article in Journal of food and drug analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Functional dyspepsia (FD) is a disorder of gut-brain interaction involving heterogeneous motor, sensory, immune, and oxidative stress-related mechanisms. Simotang oral liquid (SMT), a traditional Chinese medicine formulation used for dyspeptic and gastrointestinal motility-related symptoms, has not been evaluated with an integrated clinical, functional, and molecular framework. This single-arm prospective pre-post study assessed gastric emptying by the 13C-octanoic acid breath test, gastric electrical activity by electrogastrography, postprandial tolerance by nutrient drink testing, symptom scores, serum biomarkers, and gastric antral tissue markers in patients with FD. FD-like mice were used for charcoal meal transit, smooth muscle strip tension, calcium channel blockade, and mucosal RNA sequencing. Public transcriptomic data from GSE169304 were analyzed to characterize FD-associated duodenal mucosal molecular features. SMT treatment was associated with reduced gastric emptying half-time, improved 3-cpm stability, lower gastric dysrhythmia, reduced Nepean Dyspepsia Index and Gastroparesis Cardinal Symptom Index scores, increased motilin and gastrin levels, lower malondialdehyde, higher superoxide dismutase activity, and lower tumor necrosis factor alpha and interleukin-6 levels. Paired gastric antral biopsy analyses showed increased α-smooth muscle actin and higher phosphorylation ratios of myosin light chain kinase and myosin light chain after SMT treatment. In mice, SMT increased intestinal transit, acetylcholine-induced smooth muscle tension, Cav1.2 abundance, calmodulin fluorescence, and p-MLCK/p-MLC signaling, while nifedipine reduced the SMT-associated phosphorylation changes. Transcriptomic analyses showed enrichment of smooth muscle contraction, calcium signaling, oxidative stress response, and Nrf2-related antioxidant pathways, while protein analyses showed reduced canonical NF-κB activation markers. The data are consistent with Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.